Pharmaceuticals

Calcitonin Gene-Related Peptide (CGRP) Inhibitors Industry Forecast to Hit $4.58 Billion by 2029 With a Strong 9.9% CAGR

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Size During 2025–2029?

The calcitonin gene-related peptide (cgrp) inhibitors market size has shown substantial expansion in recent years. Its valuation is anticipated to increase from $2.87 billion in 2024 to $3.14 billion in 2025, advancing at a compound annual growth rate (CAGR) of 9.6%. This historical market expansion stems from increased investments in research and development, a rise in new drug approvals, an escalating demand for non-opioid pain relievers, and a heightened emphasis on personalized medicine.

The calcitonin gene-related peptide (cgrp) inhibitors market is projected to experience substantial expansion over the upcoming years. It is anticipated to reach a valuation of $4.58 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 9.9%. This projected growth within the forecast period can be primarily attributed to factors such as the increasing occurrence of migraine, the rising acceptance of preventive migraine therapies, heightened patient understanding, and an expansion in healthcare spending. Key developments expected during this period include advancements in drug formulation technology, the incorporation of digital health solutions, progress in precision medicine, and improvements in biosimilar technologies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24182&type=smp

What Are The Drivers Pushing New Developments In The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?

The rising occurrence of migraine is anticipated to drive the future expansion of the calcitonin gene-related peptide (CGRP) inhibitors market. A migraine is a severe headache often causing throbbing pain, typically on one side of the head, and is frequently accompanied by nausea, vomiting, and heightened sensitivity to light and sound. This increased prevalence of migraine is attributed to elevated stress levels, as chronic stress activates specific neural pathways. Calcitonin gene-related peptide (CGRP) inhibitors aid in migraine management by offering a targeted, preventive mechanism that is compatible with both acute and chronic care regimens. They work by efficiently blocking CGRP receptors, which reduces headache frequency and severity, thereby enhancing patient well-being and daily functioning. For instance, in January 2023, a report by the National Library of Medicine, a US-based health information institution, stated that the global prevalence of migraine falls between 14% and 15%, contributing to 4.9% of the global disease burden. Therefore, the growing incidence of migraine is fueling the growth of the calcitonin gene-related peptide (CGRP) inhibitors market.

Which Key Segments Fueling The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?

The calcitonin gene-related peptide (cgrp) inhibitors market covered in this report is segmented –

1) By Type Of Inhibitor: Monoclonal Antibodies, Small Molecules, Peptides

2) By Mechanism Of Action: Anti-Calcitonin Gene-Related Peptide (CGRP) Ligand, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist

3) By Route of Administration: Oral, Nasal, Intravenous

4) By Treatment: Preventive Migraine Treatment, Acute Migraine Treatment

5) By End User: Hospitals, Specialty Clinics, Mail Order Pharmacies, Retail Pharmacies

Subsegments:

1) By Monoclonal Antibodies: Erenumab (Aimovig), Eptinezumab (Vyepti), Fremanezumab (Ajovy), Galcanezumab (Emgality)

2) By Small Molecules: Ubrogepant, Rimegepant, Atogepant, Zavegepant

3) By Peptides: Calcitonin Gene-Related Peptide (CGRP) Antagonist Peptides, Modified Calcitonin Gene-Related Peptide (CGRP) Analogs, Intranasal Peptide Formulations, Peptide-Based Delivery Systems

Which Ongoing Trends Are Expected To Shape The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Outlook?

Leading companies in the calcitonin gene-related peptide (CGRP) inhibitors market are concentrating on developing innovative products to secure approvals, such as calcitonin gene-related peptide (CGRP) receptor antagonists, aiming to enhance migraine treatment effectiveness, broaden therapeutic applications, and offer more convenient administration methods like oral and intranasal formulations. A calcitonin gene-related peptide (CGRP) receptor antagonist is a medication that inhibits the calcitonin gene-related peptide (CGRP) receptor to block pain signaling related to migraines. For example, in April 2023, AbbVie Inc., a US-based biotech company, received authorization from the U.S. Food and Drug Administration (FDA) for QULIPTA (atogepant) to manage chronic migraine in adults. QULIPTA is an oral calcitonin gene-related peptide (CGRP) receptor antagonist that functions by blocking calcitonin gene-related peptide (CGRP) receptors, which are implicated in the pathophysiology of migraine, thereby assisting in the prevention of migraine attacks.

Which Major Industry Participants Are Leading The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Growth?

Major companies operating in the calcitonin gene-related peptide (CGRP) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Kissei Pharmaceutical Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., Shin Nippon Biomedical Laboratories Ltd., Sosei Group Corporation, Nuvie Bio Inc., Vaxxinity Inc., Acherx LLC, AfaSci Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/calcitonin-gene-related-peptide-cgrp-inhibitors-global-market-report

What Are The Key Regional Factors Influencing The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Growth?

North America was the largest region in the calcitonin gene-related peptide (CGRP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin gene-related peptide (CGRP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24182&type=smp

Browse Through More Reports Similar to the Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market 2025, By The Business Research Company

Her2 Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report

Checkpoint Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report

Protein Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/protein-inhibitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795